Honest CagriSema reviews: REDEFINE trial weight-loss numbers, side effects, availability, and what Reddit users say about this unapproved drug.
CagriSema reviews generally reach the same conclusion: the once-weekly combination of cagrilintide and semaglutide produced about 22.7% average weight loss at 68 weeks in its largest phase 3 trial, the biggest figure reported for an obesity drug candidate so far. CagriSema is not FDA-approved for human use in the United States, and it cannot be prescribed or legally purchased. Any vendor selling something called CagriSema today is selling an unverified product.
What Is CagriSema?
CagriSema is a single subcutaneous injection that pairs two appetite-suppressing molecules from two different drug classes. Novo Nordisk built it to test whether hitting two hormone pathways at once beats either drug alone.
- Cagrilintide — a long-acting amylin analog. Amylin is a hormone released alongside insulin that slows stomach emptying and increases feelings of fullness.
- Semaglutide — a GLP-1 receptor agonist, the active ingredient in Ozempic and Wegovy.
Both are delivered in one weekly shot, typically titrated upward over several weeks to limit gastrointestinal side effects. The dose studied in phase 3 was 2.4 mg semaglutide plus 2.4 mg cagrilintide.
| Component | Drug class | Primary mechanism |
|---|---|---|
| Cagrilintide 2.4 mg | Amylin analog | Slows gastric emptying, increases satiety |
| Semaglutide 2.4 mg | GLP-1 receptor agonist | Reduces appetite, slows gastric emptying |
| CagriSema | Fixed-dose combination | Both pathways at once |
What the Clinical Trials Found
The REDEFINE program is the primary source of human data. REDEFINE 1 enrolled roughly 3,400 adults with obesity or overweight plus at least one weight-related condition, and none of them had type 2 diabetes. Treatment ran for 68 weeks.
| Treatment arm | Average weight loss at 68 weeks |
|---|---|
| CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) | 22.7% |
| Semaglutide 2.4 mg alone | 16.1% |
| Cagrilintide 2.4 mg alone | 11.8% |
| Placebo | 2.3% |
Those are averages, not promises. Some participants lost far more than 22.7% and some lost much less. Everyone in the trial also received diet and activity counseling, which is standard in obesity research and part of why the placebo group still lost a small amount of weight.
REDEFINE 2 tested CagriSema in adults with type 2 diabetes and overweight or obesity. That study reported roughly 13.7% average weight loss at 68 weeks, which is lower than REDEFINE 1 and typical when type 2 diabetes is present.
CagriSema has not been compared head-to-head against tirzepatide (Zepbound), so any claim that one drug is definitively stronger rests on cross-trial comparisons that researchers consider unreliable.
Side Effects and Tolerability
Gastrointestinal effects dominate the side effect profile, just as they do with other GLP-1 and amylin drugs. The most frequent complaints in REDEFINE 1 were nausea, vomiting, diarrhea, and constipation.
- Most GI events were mild to moderate and clustered during dose escalation.
- A minority of participants stopped treatment because of side effects, at rates higher than placebo.
- Class-level risks include pancreatitis, gallbladder disease, and gastroparesis.
- Semaglutide carries a boxed warning about thyroid C-cell tumors seen in rodents; the human relevance is unknown.
CagriSema is not recommended during pregnancy. Anyone with a personal or family history of pancreatitis, gallbladder problems, or medullary thyroid cancer should discuss the risk profile with a clinician before considering this class of medication.
Because CagriSema has not been reviewed by the FDA, no US prescribing information or post-marketing safety database exists for the combination.
What CagriSema Reddit Threads Actually Say
CagriSema Reddit discussion is dominated by two themes: excitement about the 22.7% figure and frustration that the drug is unavailable. Almost nobody posting in those threads has actually used it, because it cannot legally be bought.
That creates a signal problem. A gray-market product marketed as CagriSema could be a different molecule, a lower dose, or a simple mix of semaglutide and something else. The same pattern shows up in aod 9604 reviews and thymosin beta 4 reviews, where user reports routinely outrun published human data.
Where forums are genuinely useful is comparison. Long-time GLP-1 users stack CagriSema trial curves against their own experience on tirzepatide or semaglutide, and their practical notes on titration, hydration, and protein intake carry across these drugs.
Availability, Timeline, and Cost
CagriSema remains investigational. Novo Nordisk has said it intends to file for regulatory approval, but no submission had been accepted by the FDA as of late 2025, and no launch date has been announced.
| Product | US status | Approximate monthly list price |
|---|---|---|
| CagriSema | Investigational, not approved | Unknown |
| Wegovy (semaglutide 2.4 mg) | FDA-approved for weight management | About $1,300+ |
| Zepbound (tirzepatide) | FDA-approved for weight management | About $1,000+ |
If approved, CagriSema would likely launch near the price of other branded obesity drugs, and insurers would probably require prior authorization plus a documented BMI threshold. No one can quote a real CagriSema price today.
How to Judge a CagriSema Review
Many pages ranking for this topic are rewrites of the same press release. A review worth reading does a few specific things.
- Cites the peer-reviewed REDEFINE publications rather than a news summary.
- Separates trial averages from individual anecdotes.
- States the approval status plainly instead of implying you can buy it.
- Discloses its own funding or affiliate relationships.
That standard applies across the whole injectable and supplement world. Reviews of approved drugs, such as those collected in vyleesi reviews, can be checked against FDA labeling and trial data. If you have read dsip reviews or liposomal glutathione reviews, you already know how quickly a page can slide from evidence into marketing.
No review should promise an outcome. CagriSema was studied as a chronic weight-management medication used alongside diet and physical activity, not as a cure.
Frequently Asked Questions
Is CagriSema FDA-approved or available in the US?
No. CagriSema is still an investigational combination therapy, and Novo Nordisk has not received FDA approval for it. It cannot be prescribed by a US doctor or dispensed by a pharmacy. Products sold online as CagriSema are unverified and have not been evaluated for identity, purity, or sterility.
How much weight loss did CagriSema produce in clinical trials?
In the REDEFINE 1 phase 3 trial, participants taking CagriSema lost an average of about 22.7% of their body weight at 68 weeks, compared with 16.1% on semaglutide 2.4 mg, 11.8% on cagrilintide 2.4 mg, and 2.3% on placebo. In REDEFINE 2, which enrolled adults with type 2 diabetes, average weight loss was about 13.7% at 68 weeks. Individual results varied widely in both trials.
What do Reddit users say about CagriSema?
Most CagriSema Reddit threads focus on trial results and on frustration that the drug is not yet available, and very few posters report personal experience with it. Some commenters compare the REDEFINE data with their own results on tirzepatide or semaglutide. Anecdotes from unapproved sellers should be treated as unverifiable, since the product's actual contents cannot be confirmed.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.